Journal
TRANSLATIONAL ONCOLOGY
Volume 6, Issue 4, Pages 392-397Publisher
ELSEVIER SCIENCE INC
DOI: 10.1593/tlo.13253
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R01 CA073808, R44 CA128141, T32GM08349, RR13790]
- William R. & Dorothy E. Sullivan Wisconsin Distinguished Graduate Fellowship, Department of Biochemistry
- National Science Foundation [BIR-9512577]
- W.M. Keck Foundation
Ask authors/readers for more resources
Human pancreatic ribonuclease (RNase 1) is a small secretory protein that catalyzes the cleavage of RNA. This highly cationic enzyme can enter human cells spontaneously but is removed rapidly from circulation by glomerular filtration. Here, this shortcoming is addressed by attaching a poly(ethylene glycol) (PEG) moiety to RNase 1. The pendant has no effect on ribonucleolytic activity but does increase persistence in circulation. The RNase 1-PEG conjugates inhibit the growth of tumors in a xenograft mouse model of human lung cancer. Both retention in circulation and tumor growth inhibition correlate with the size of the pendant PEG. A weekly dose of the 60-kDa conjugate at 1 mu mol/kg inhibited nearly all tumor growth without affecting body weight. Its molecular efficacy is similar to 5000-fold greater than that of erlotinib, which is a small molecule in clinical use for the treatment of lung cancer. These data demonstrate that the addition of a PEG moiety can enhance the in vivo efficacy of human proteins that act within cells and highlight a simple means of converting an endogenous human enzyme into a cytotoxin with potential clinical utility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available